Cancer biomarkers and nothing but processes or substances used to indicate the presence of cancer cells in the human body. They are created by either the cancer tissues themselves or any other cell to combat the response of cancer in the body. These elements are found in the bodily fluids, tumour tissues, urine, stool, blood and other such issues. The facility high-speed non-invasive process of diagnosis using the proteomics and genomics and stimulate the process of Cancer detection. The rise of cancer cells in different parts of the body has comparatively increased during the last few years, which has convulsively made Technology soaring and create a dish for the global cancer biomarkers market.
Growth factors and trends With the ease of understanding of diseases and better target discoveries and biomarker enabled drug discovery facilities, the global market has registered a sale of 10.3 1 billion USD during the year 2016. It is only expected to show an upward rise in the curve with a CAGR of 12.2%, which is around 20 point 48 billion USD by the year 2022. With aggressive technological advancements in products and enhanced accuracy and speed of genetic biomarker diagnosis and discovery, the market players have created height throughput in terms of expansion of the genetic biomarkers market. With the dynamically aggressive technological discoveries and more key players making a way in the market, it can easily be estimated that by the year 2022 industry will segment itself further into discoveries and diagnosis of the fatal disease. Hence it is a safe bet to forecast that the cancer biomarkers industry is on an upward rise and will continue to do so through the year 2023.